TPG announces growth investment in K2 Medical, terms not disclosed

TPG announced a significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform specializing in central nervous system trials for leading pharma and biotech sponsors. TPG is partnering with K2’s management team to continue building a world class research platform. Terms were not disclosed. Founded by CEO, Sean Stanton, and Chief Medical Officer, Brandon Lenox, DO, K2 operates several de novo clinical trial sites across Florida. The Company specializes in conducting multi-phase clinical trials in complex therapeutic areas including Alzheimer’s, psychiatry, and liver disease, among others. K2’s model is centered around strong site operators, and the Company has successfully differentiated itself by developing direct relationships with pharma and biotech sponsors, while executing an impressive de novo regional growth strategy.